PREVENT INFECTION

Immunizations in Primary Care

Immunization decisions integrate the patient’s age, documented vaccination history, immune function, pregnancy status, and exposure risks. The schedule provides a starting point; its accompanying notes establish how the recommendation applies to an individual patient.

Use the current schedule, catch-up guidance, and vaccine-specific recommendations together. Recommendations and available products can change between annual schedule publications (Centers for Disease Control and Prevention [CDC], 2025).

How Vaccines Produce Protection

Active immunization stimulates the recipient’s immune response and immunologic memory. Passive immunization supplies antibodies that provide more immediate, temporary protection.

Live attenuated vaccines replicate to generate an immune response. Examples include measles-mumps-rubella and varicella vaccines. Replication creates important restrictions during pregnancy and substantial immunosuppression.

Nonlive vaccines include inactivated organisms, selected antigens, toxoids, conjugate vaccines, and platforms that direct cells to produce an antigen. Toxoids generate immunity against bacterial toxins. Conjugating a polysaccharide to a protein carrier improves T-cell-dependent responses and memory, supporting effectiveness in young children.

Multiple doses may establish an adequate initial response or restore protection over time. These purposes differ between vaccine products (CDC, 2024).

Apply the Pediatric Schedule

Review the complete record at every preventive visit, including doses administered elsewhere.

Representative routine scheduling patterns include:

Infancy: Hepatitis B vaccination begins at birth under the linked schedule. DTaP, inactivated poliovirus, Hib, pneumococcal conjugate, and rotavirus series begin during infancy.
Early childhood: First routine MMR and varicella doses are generally given at 12–15 months. Hepatitis A begins at 12–23 months as a two-dose series separated by at least six months.
Preschool years: Review DTaP, poliovirus, MMR, and varicella completion before school entry.
Adolescence: Review Tdap, HPV, and meningococcal vaccination, along with missed earlier doses.
Seasonal prevention: Review influenza and current COVID-19 recommendations, including age-appropriate products and prior-dose history.

Product choice affects Hib and rotavirus dose counts. Rotavirus also has upper age limits: the first dose must be given before 15 weeks of age, and the series completed by eight months. It cannot simply be restarted later (CDC, n.d.-b).

Apply HPV Scheduling

Routine HPV vaccination is recommended at ages 11–12 years and can begin at age nine. Catch-up vaccination is recommended through age 26.

For an immunocompetent patient starting before age 15, the usual series is two doses 6–12 months apart. A three-dose schedule applies when starting at age 15 or older and for immunocompromised patients. Selected adults ages 27–45 may benefit through shared clinical decision-making.

The age at the first dose determines the usual series requirement. A delayed second dose does not automatically convert a two-dose series into three doses (CDC, n.d.-d).

Apply the Adult Schedule

Adult review includes incomplete childhood vaccination, routine adult recommendations, and risk-based indications.

Tdap should be documented, followed by Td or Tdap boosters every ten years. Tdap is recommended during each pregnancy, preferably during the early portion of 27–36 weeks. Wound management may require a different interval.

Hepatitis B vaccination is routinely recommended for adults ages 19–59; older adults are assessed according to risk and desire for protection. Hepatitis A, MMR, varicella, and meningococcal vaccination depend on immunity and risk factors.

Influenza vaccination is reviewed annually. COVID-19 decisions require the current product-specific and age-specific recommendation rather than reliance on a prior season’s regimen (CDC, n.d.-a).

Pneumococcal, Shingles, and RSV Decisions

Pneumococcal vaccination: Adults ages 50 and older who have not received a pneumococcal conjugate vaccine, or whose history is unknown, can receive PCV15, PCV20, or PCV21 under current recommendations. PCV15 generally requires subsequent PPSV23; PCV20 or PCV21 completes the recommended series in this situation. Earlier vaccination may be indicated by risk. Prior PCV or PPSV23 doses change the pathway (CDC, n.d.-e).

Recombinant zoster vaccination: A two-dose series is recommended for adults ages 50 and older and for immunodeficient or immunosuppressed adults ages 19 and older. Prior shingles does not remove the indication. The usual interval is 2–6 months; selected immunocompromised patients may use a shorter interval (CDC, n.d.-g).

RSV vaccination: Current adult guidance recommends one dose for adults ages 75 and older and adults ages 50–74 at increased risk of severe RSV disease. It is not currently an annual vaccine. Maternal vaccination uses Pfizer Abrysvo at 32 0/7 through 36 6/7 weeks of gestation, generally during September through January in most of the continental United States. Most infants need either maternal vaccination or a recommended long-acting infant RSV antibody, not both; location, season, prior maternal vaccination, and infant risk affect the final plan (CDC, n.d.-f).

Catch-Up and Spacing

An interrupted vaccine series generally continues from the last valid dose. Determine which doses count by checking minimum ages, minimum intervals, and product history.

For example, an adolescent who received a valid first HPV dose at age 13 and returns at age 16 may still qualify for the two-dose schedule if immunocompetent and the interval is adequate.

Most vaccines can be administered during the same visit. Injectable or intranasal live vaccines that are not given on the same day generally require at least four weeks between doses. Antibody-containing products can interfere with selected live vaccines, requiring product-specific spacing (CDC, 2024).

Contraindications and Precautions

A contraindication generally means the vaccine should not be administered. A precaution requires weighing the risks and benefits or deferring until the condition improves.

Examples include severe allergic reaction to a previous dose or component, pregnancy for selected live vaccines, and substantial immunosuppression for live vaccines. Moderate or severe acute illness is commonly a precaution.

Mild illness, antibiotic use, and a family history of nonspecific vaccine reactions generally do not justify routine deferral. Apply the specific vaccine’s criteria (CDC, n.d.-c).

Complete the Visit

Document the vaccine, date, product, dose, route, site, lot information, and required educational information. Explain expected reactions and symptoms requiring urgent evaluation.

Schedule the next dose before the patient leaves. For patients with complex records, document which prior doses were accepted and the reasoning used to construct the remaining schedule.

Related YourDNP Resources

Content last reviewed:

September 15, 2026

References

Centers for Disease Control and Prevention. (2024, July 24). Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html

Centers for Disease Control and Prevention. (2025, July 2). Healthcare professionals: Immunization schedules. https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html

Centers for Disease Control and Prevention. (n.d.-a). Adult immunization schedule notes. Retrieved September 15, 2026, from https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-notes.html

Centers for Disease Control and Prevention. (n.d.-b). Child immunization schedule notes. Retrieved September 15, 2026, from https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-notes.html

Centers for Disease Control and Prevention. (n.d.-c). Contraindications and precautions. Retrieved September 15, 2026, from https://www.cdc.gov/vaccines/hcp/imz-best-practices/contraindications-precautions.html

Centers for Disease Control and Prevention. (n.d.-d). HPV vaccine recommendations. Retrieved September 15, 2026, from https://www.cdc.gov/hpv/hcp/vaccination-considerations/index.html

Centers for Disease Control and Prevention. (n.d.-e). Pneumococcal vaccine recommendations. Retrieved September 15, 2026, from https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html

Centers for Disease Control and Prevention. (n.d.-f). RSV vaccine guidance for adults. Retrieved September 15, 2026, from https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html

Centers for Disease Control and Prevention. (n.d.-g). Shingles vaccine recommendations. Retrieved September 15, 2026, from https://www.cdc.gov/shingles/hcp/vaccine-considerations/